Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

AIM: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Brian, Miles-Thomas, Jennifer, Park, Amy J, Nguyen, Victor B, Tung, Amy, Gillard, Patrick, Lalla, Anjana, Nitti, Victor W, Chermansky, Christopher J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288955/
https://www.ncbi.nlm.nih.gov/pubmed/36655745
http://dx.doi.org/10.2217/cer-2022-0089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288955/
https://www.ncbi.nlm.nih.gov/pubmed/36655745
http://dx.doi.org/10.2217/cer-2022-0089

Ejemplares similares